Literature DB >> 8674120

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

B J Doranz1, J Rucker, Y Yi, R J Smyth, M Samson, S C Peiper, M Parmentier, R G Collman, R W Doms.   

Abstract

Here, we show that the beta-chemokine receptor CKR-5 serves as a cofactor for M-tropic HIV viruses. Expression of CKR-5 with CD4 enables nonpermissive cells to form syncytia with cells expressing M-tropic, but not T-tropic, HIV-1 env proteins. Expression of CKR-5 and CD4 enables entry of a M-tropic, but not a T-tropic, virus strain. A dual-tropic primary HIV-1 isolate (89.6) utilizes both Fusin and CKR-5 as entry cofactors. Cells expressing the 89.6 env protein form syncytia with QT6 cells expressing CD4 and either Fusin or CKR-5. The beta-chemokine receptors CKR-3 and CKR-2b support HIV-1 89.6 env-mediated syncytia formation but do not support fusion by any of the T-tropic or M-tropic strains tested. Our results suggest that the T-tropic viruses characteristic of disease progression may evolve from purely M-tropic viruses prevalent early in virus infection through changes in the env protein that enable the virus to use multiple entry cofactors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674120     DOI: 10.1016/s0092-8674(00)81314-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  621 in total

1.  Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.

Authors:  D Schenten; L Marcon; G B Karlsson; C Parolin; T Kodama; N Gerard; J Sodroski
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

3.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.

Authors:  I I Singer; S Scott; D W Kawka; J Chin; B L Daugherty; J A DeMartino; J DiSalvo; S L Gould; J E Lineberger; L Malkowitz; M D Miller; L Mitnaul; S J Siciliano; M J Staruch; H R Williams; H J Zweerink; M S Springer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Physiological coreceptor use by dual-tropic HIV-1: one plus one equals one.

Authors:  B J Rollins
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

6.  Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.

Authors:  S Glushakova; Y Yi; J C Grivel; A Singh; D Schols; E De Clercq; R G Collman; L Margolis
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

7.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Authors:  T Dragic; A Trkola; D A Thompson; E G Cormier; F A Kajumo; E Maxwell; S W Lin; W Ying; S O Smith; T P Sakmar; J P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

9.  Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.

Authors:  K M Haan; W W Kwok; R Longnecker; P Speck
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

10.  Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains.

Authors:  A L Edinger; C Blanpain; K J Kunstman; S M Wolinsky; M Parmentier; R W Doms
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.